API segment to see slowdown in FY24 * IPCA delivered lower-than-expected 1QFY24 financial perf...
Ipca Laboratories is currently trading at Rs. 913.45, up by 25.35 points or 2.85% from its previo...
We attended the analyst/investor call hosted by IPCA Laboratories (IPCA) regarding the Unichem La...
Shares of Indian pharmaceutical firm Ipca Laboratories fell as much as 9.1% to a near three-year ...
Our meeting with Mr. Ajit Jain, Jt. MD and Mr. Harish Kamath, CS, provided insights into IPCA&rsq...
Margin pain ending; reinstate BUY from ADD Result Synopsis IPCA reported a largely in-line ...
Progressing steadily to reclaim the growth path * We met with the management of IPCA recently ...
Ipca Laboratories is currently trading at Rs. 856.00, up by 1.60 points or 0.19% from its previou...
Escalated operating cost hurts profitability Domestic formulation – a saving grace * ...
IPCA LABORATORIES LTD (NSE SYMBOL: IPCALAB | BSE CODE: 524494) * The stock after a massive cor...
On course to revive earnings growth We recently met the management of IPCA lab to understand i...
The company reported standalone net profit of Rs 110.41 crore for the quarter ended March 31, 202...
Branded generics at play; risk-reward favorable Some hiccups expected in the CIS/API/UK busine...
Rev growth to overcome near term margin challenge Our view IPCA clocked a tepid revenue qua...
Subdued quarter on expected lines Ipca’s (IPCA) Q3FY22 revenue/EBITDA was 2%/3% below co...
Exports/API drag earnings The Domestic Formulation segment remains an outperformer * I...
Long-run growth prospects intact We interacted with Joint MD of Ipca Laboratories (Ipca), Mr. ...
Strong DF business offset by weak exports/API performance Higher RM/logistic costs to keep mar...
Temporary margin hiccup; rev drivers intact Our view IPCA domestic business continues to ex...
Strong performance despite GPM pressure… About the stock: Ipca is a fully integrated ph...
Strong traction in DF/API; exports to pick-up gradually Opex on the rise due to higher RM/logi...
Our view Q1 FY22 might again be a high water mark in domestic revenue growth as base compariso...
4Q – an aberration; outlook remains intact Well-placed to outperform in Branded Generics...
Result Highlights * Q4 revenues up 3.8% YoY driven by branded exports (+32% YoY), institutiona...
Below are Quote on Ipca labs reported a weak set of numbers for Q4FY21 by Mr.&nb...
On a steady footing From our interaction with the management, we believe Ipca Laboratories (I...
Steady quarter * We maintain our Hold rating on Ipca with a TP of Rs2,150 (unchanged) post a s...
Buy Ipca Laboratories For Target Rs. 2,150 * We maintain our Hold rating on Ipca wit...
Better operating leverage drives earnings API capacity expansion on track * Ipca Laborato...
Q3 FY21 call highlights * Robust margin guidance of 25‐26% implies OPM crosses previous all t...